Survival and dementia in <scp>GBA</scp>â€asso
<scp>T</scp>he mutation matters

Annals of Neurology

80, 662-673

DOI: 10.1002/ana.24777

Citation Report

#	Article	IF	Citations
1	Glucocerebrosidase, <scp>P</scp>arkinson disease, and the â€œsenses and intellectâ€• Annals of Neurology, 2016, 80, 660-661.	2.8	0
2	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	2.2	88
3	The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron, 2017, 93, 737-746.	3.8	127
4	Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature. European Journal of Neurology, 2017, 24, 561.	1.7	41
5	Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2699-2704.	3.3	165
6	Cognitive decline in Parkinson disease. Nature Reviews Neurology, 2017, 13, 217-231.	4.9	705
7	Genetics of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 197-231.	0.9	76
8	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	4.9	131
9	Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinsonâ€™s disease. Expert Review of Molecular Diagnostics, 2017, 17, 771-780.	1.5	23
10	Parkinson disease. Nature Reviews Disease Primers, 2017, 3, 17013.	18.1	3,048
11	Subtypes of Parkinsonâ€™s Disease: What Do They Tell Us About Disease Progression?. Current Neurology and Neuroscience Reports, 2017, 17, 34.	2.0	100
12	Movement disorders in 2016: from genes to phenotypes. Lancet Neurology, The, 2017, 16, 9-10.	4.9	4
13	The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Scientific Reports, 2017, 7, 12702.	1.6	62
14	What would Dr. James Parkinson think today? Mutations in betaâ€glucocerebrosidase and risk of Parkinson's disease. Movement Disorders, 2017, 32, 1341-1342.	2.2	3
15	Cerebrospinal fluid Î²â€glucocerebrosidase activity is reduced in parkinson's disease patients. Movement Disorders, 2017, 32, 1423-1431.	2.2	132
16	GBA mutations in Parkinson disease: earlier death but similar neuropathological features. European Journal of Neurology, 2017, 24, 1363-1368.	1.7	27
17	An update on the genetics of dementia with Lewy bodies. Parkinsonism and Related Disorders, 2017, 43, 1-8.	1.1	31
18	N370Sâ€GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Movement Disorders, 2017, 32, 1409-1422.	2.2	86

#	Article	IF	Citations
19	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473.	0.6	49
21	Cognition in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 557-583.	0.9	51
22	Biomarkers of Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 259-289.	0.9	10
23	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. Neurobiology of Aging, 2017, 58, 239.e1-239.e7.	1.5	6
24	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	0.5	112
25	Glucocerebrosidase Mutations in Parkinson Disease. Journal of Parkinson's Disease, 2017, 7, 411-422.	1.5	108
26	A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences, 2017, 18, 441.	1.8	497
27	Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinsonâ€™s Disease. Frontiers in Genetics, 2017, 8, 177.	1.1	58
28	Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism, 2018, 13, 107-118.	1.2	78
29	Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 50, 94-98.	1.1	23
30	Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications. Neuroscientist, 2018, 24, 540-559.	2.6	81
31	The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS Journal, 2018, 285, 3591-3603.	2.2	99
32	The genetics of Parkinson disease. Ageing Research Reviews, 2018, 42, 72-85.	5.0	398
33	Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Movement Disorders, 2018, 33, 684-696.	2.2	140
34	Dementia with Lewy bodies and Parkinsonâ€™s disease-dementia: current concepts and controversies. Journal of Neural Transmission, 2018, 125, 615-650.	1.4	200
35	SPECT Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 225-260.	0.9	3
36	Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Frontiers in Neurology, 2018, 9, 857.	1.1	15
37	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Movement Disorders, 2018, 33, 1656-1660.	2.2	14

#	Article	IF	Citations
38	Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current Challenges and Emerging Insights. Frontiers in Molecular Neuroscience, 2018, 11, 370.	1.4	52
39	A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-7.	0.6	29
40	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. Journal of Neuroscience, 2018, 38, 9375-9382.	1.7	32
41	PET Molecular Imaging in Familial Parkinson's Disease. International Review of Neurobiology, 2018, 142, 177-223.	0.9	6
42	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism and Related Disorders, 2018, 55, 45-49.	1.1	90
43	Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimer's and Dementia, 2018, 14, 1293-1301.	0.4	23
44	Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes. Frontiers in Neuroanatomy, 2018, 12, 52.	0.9	19
45	Cognition among individuals along a spectrum of increased risk for Parkinsonâ€™s disease. PLoS ONE, 2018, 13, e0201964.	1.1	33
46	GBA-Associated Parkinsonâ€™s Disease and Other Synucleinopathies. Current Neurology and Neuroscience Reports, 2018, 18, 44.	2.0	106
47	The GBA p.Trp378Gly mutation is a probable Frenchâ€Canadian founder mutation causing Gaucher disease and synucleinopathies. Clinical Genetics, 2018, 94, 339-345.	1.0	9
48	Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. European Journal of Medical Genetics, 2019, 62, 65-69.	0.7	49
49	Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinsonâ€™s Disease and Dementia with Lewy Bodies. Molecular Neurobiology, 2019, 56, 1344-1355.	1.9	97
50	Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 8-19.	1.1	31
51	Patient's perception: shorter and more severe prodromal phase in GBA â€associated PD. European Journal of Neurology, 2019, 26, 694-698.	1.7	13
52	Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Movement Disorders, 2019, 34, 1262-1273.	2.2	25
53	Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?. Trends in Neurosciences, 2019, 42, 631-643.	4.2	22
54	Genetic analysis of Mendelian mutations in a large UK population-based Parkinsonâ€™s disease study. Brain, 2019, 142, 2828-2844.	3.7	62
55	Parkinsonâ€™s progression prediction using machine learning and serum cytokines. Npj Parkinson's Disease, 2019, 5, 14.	2.5	63

#	Article	IF	Citations
56	Autophagic- and Lysosomal-Related Biomarkers for Parkinsonâ€™s Disease: Lights and Shadows. Cells, 2019, 8, 1317.	1.8	23
57	Classification of GBA Variants and Their Effects in Synucleinopathies. Movement Disorders, 2019, 34, 1581-1582.	2.2	8
58	Deep brain stimulation and genetic variability in Parkinsonâ€™s disease: a review of the literature. Npj Parkinson's Disease, 2019, 5, 18.	2.5	23
59	Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiology of Disease, 2019, 127, 1-12.	2.1	13
60	SNCA Rep1 promoter variability influences cognition in Parkinson's disease. Movement Disorders, 2019, 34, 1232-1236.	2.2	13
61	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism and Related Disorders, 2019, 65, 39-48.	1.1	69
62	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	4.9	116
63	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alphaâ€synuclein profile. Movement Disorders, 2019, 34, 1069-1073.	2.2	24
64	GBA, Gaucher Disease, and Parkinsonâ€™s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364.	1.8	187
65	First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L. Movement Disorders Clinical Practice, 2019, 6, 254-258.	0.8	4
66	Mind the gaps: What we don't know about cognitive impairment in essential tremor. Parkinsonism and Related Disorders, 2019, 63, 10-19.	1.1	47
67	Targeting Î±-Synuclein in Parkinsonâ€™s Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs, 2019, 79, 797-810.	4.9	67
68	Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clinica Chimica Acta, 2019, 495, 13-24.	0.5	18
69	Parkinsonism in neurometabolic diseases. International Review of Neurobiology, 2019, 149, 355-376.	0.9	0
70	GBA1-associated parkinsonism: new insights and therapeutic opportunities. Current Opinion in Neurology, 2019, 32, 589-596.	1.8	42
71	Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy, 2019, 15, 113-130.	4.3	155
72	Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. Parkinsonism and Related Disorders, 2019, 62, 179-184.	1.1	58
73	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	2.2	73

#	Article	IF	Citations
74	The role of monogenic genes in idiopathic Parkinsonâ€™s disease. Neurobiology of Disease, 2019, 124, 230-239.	2.1	97
75	New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. Parkinsonism and Related Disorders, 2019, 59, 32-38.	1.1	25
76	Neurological effects of glucocerebrosidase gene mutations. European Journal of Neurology, 2019, 26, 388.	1.7	30
77	Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity. Neurobiology of Disease, 2019, 124, 289-296.	2.1	22
78	Genetics of REM Sleep Behavior Disorder. , 2019, , 589-609.		2
79	GBA1 mutations: Prospects for exosomal biomarkers in Î±-synuclein pathologies. Molecular Genetics and Metabolism, 2020, 129, 35-46.	0.5	11
80	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alphaâ€Synuclein Profiles. Movement Disorders, 2020, 35, 495-499.	2.2	32
81	Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genetics in Medicine, 2020, 22, 574-580.	1.1	36
82	Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinsonâ€™s disease dementia: A meta-analysis. Neuroscience Letters, 2020, 714, 134544.	1.0	5
83	Organoid and pluripotent stem cells in Parkinsonâ€™s disease modeling: an expert view on their value to drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 427-441.	2.5	21
84	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism and Related Disorders, 2020, 73, 60-71.	1.1	85
85	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinsonâ€™s disease. Journal of Medical Genetics, 2020, 57, 331-338.	1.5	36
86	LRRK2 and GBA Variants Exert Distinct Influences on Parkinsonâ€™s Disease-Specific Metabolic Networks. Cerebral Cortex, 2020, 30, 2867-2878.	1.6	35
87	Parkinsonâ€™s disease in Gaucher disease patients: whatâ€™s changing in the counseling and management of patients and their relatives?. Orphanet Journal of Rare Diseases, 2020, 15, 262.	1.2	3
88	Precision medicine in Parkinsonâ€™s disease patients with LRRK2 and GBA risk variants â€“ Letâ€™s get even more personal. Translational Neurodegeneration, 2020, 9, 39.	3.6	29
89	Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 4966.	1.8	21
90	<scp>GBAâ€Related</scp> Parkinson's Disease: Dissection of Genotypeâ€“Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83
91	Trends in Glucocerebrosides Research: A Systematic Review. Frontiers in Physiology, 2020, 11, 558090.	1.3	2

#	Article	IF	Citations
92	Therapy of Parkinson's Disease Subtypes. Neurotherapeutics, 2020, 17, 1366-1377.	2.1	42
93	Penetrance of Glucocerebrosidase (<scp>GBA</scp>) Mutations in Parkinson's Disease: A Kin Cohort Study. Movement Disorders, 2020, 35, 2111-2114.	2.2	50
96	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. , 2020, , 202-212.		0
97	Longitudinal Measurements of Glucocerebrosidase activity in Parkinsonâ€™s patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	1.7	23
98	Epidemiology and Mental Health in Old Age. , 2020, , 5-23.		0
100	Young-Onset Dementias. , 2020, , 38-49.		0
101	Rare and Unusual Dementias. , 2020, , 50-77.		0
102	Mania in Late Life. , 2020, , 78-91.		0
103	Alcohol Misuse in Older People. , 2020, , 92-104.		0
104	Drug Misuse in Older People. , 2020, , 105-115.		0
105	Mental Health in Parkinsonâ€™s Disease. , 2020, , 116-128.		0
106	The Home Assessment in Old Age Psychiatry. , 2020, , 129-138.		0
107	Driving in Dementia. , 2020, , 139-148.		0
108	Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. , 2020, , 149-160.		0
109	Biomarkers and the Diagnosis of Preclinical Alzheimerâ€™s Disease. , 2020, , 161-172.		0
110	To Scan or Not to Scan. , 2020, , 173-190.		0
111	Supporting Self-Management in Early Dementia. , 2020, , 191-201.		0
112	Psychosocial Interventions in Dementia. , 2020, , 213-222.		0

#	Article	IF	Citations
113	Palliative Care in Dementia. , 2020, , 223-242.		0
114	Review of Treatment for Late-Life Depression. , 2020, , 243-253.		0
115	Reducing the Healthcare Burden of Delirium. , 2020, , 254-265.		0
116	Controlling the Confusion. , 2020, , 266-278.		0
117	Residence Capacity. , 2020, , 305-316.		0
121	Mental Health Laws from All UK Jurisdictions. , 2020, , 279-292.		0
122	Deprivation of Liberty. , 2020, , 293-304.		0
123	Understanding the Person with Dementia. , 2020, , 317-327.		0
124	L444P Gba1 mutation increases formation and spread of Î±-synuclein deposits in mice injected with mouse Î±-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	1.1	20
125	Multivariate prediction of dementia in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 20.	2.5	25
126	<scp>GBA</scp> Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Movement Disorders, 2020, 35, 2201-2210.	2.2	55
127	Genetics of Parkinson's disease. Acta Neurologica Belgica, 2020, 120, 1297-1305.	0.5	59
128	Deep Brain Stimulation Selection Criteria for Parkinsonâ€™s Disease: Time to Go beyond CAPSIT-PD. Journal of Clinical Medicine, 2020, 9, 3931.	1.0	26
129	GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. Frontiers in Cell and Developmental Biology, 2020, 8, 562522.	1.8	10
130	The Emerging Role of the Lysosome in Parkinsonâ€™s Disease. Cells, 2020, 9, 2399.	1.8	63
131	Common Variants Coregulate Expression of <scp>GBA</scp> and Modifier Genes to Delay Parkinson's Disease Onset. Movement Disorders, 2020, 35, 1346-1356.	2.2	30
132	The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinsonâ€™s Disease. Biomolecules, 2020, 10, 912.	1.8	18
133	Î²-Glucocerebrosidase activity in GBA -linked Parkinson disease. Neurology, 2020, 95, e685-e696.	1.5	27

#	Article	IF	Citations
134	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clinica Chimica Acta, 2020, 506, 55-66.	0.5	2
135	GBA variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
136	A <scp>Largeâ€Scale</scp> Full <scp>GBA1</scp> Gene Screening in Parkinson's Disease in the Netherlands. Movement Disorders, 2020, 35, 1667-1674.	2.2	41
137	Mutation Analysis of the Genes Associated with Parkinsonâ€™s Disease in a Finnish Cohort of Early-Onset Dementia. Journal of Alzheimer's Disease, 2020, 76, 955-965.	1.2	0
138	Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. BJ Psych Advances, 2020, 26, 333-342.	0.5	8
139	Lysosomal Ceramide Metabolism Disorders: Implications in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 594.	1.0	31
140	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Crossâ€Sectional Study. Movement Disorders, 2020, 35, 833-844.	2.2	48
141	Disease modification and biomarker development in Parkinson disease. Neurology, 2020, 94, 481-494.	1.5	103
142	The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's Disease, 2020, 10, 301-313.	1.5	35
143	Gait asymmetry in glucocerebrosidase mutation carriers with Parkinsonâ€™s disease. PLoS ONE, 2020, 15, e0226494.	1.1	8
144	Glucocerebrosidase Defects as a Major Risk Factor for Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 97.	1.7	65
145	A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. Movement Disorders, 2020, 35, 1249-1253.	2.2	27
146	A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 673-674.	0.9	9
147	Age at Onset of Parkinsonâ€™s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. Journal of Parkinson's Disease, 2020, 10, 1123-1132.	1.5	21
148	Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 695-702.	0.9	48
149	Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 33-36.	0.8	5
150	Brain Microglial Activation Increased in Glucocerebrosidase (<scp>GBA</scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	2.2	49
151	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	2.2	101

#	Article	IF	Citations
152	Genetic Risk Factors and Lysosomal Function in Parkinson Disease. , 0, , .		0
153	Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report. BMC Neurology, 2021, 21, 17.	0.8	3
154	Cross-talks among GBA mutations, glucocerebrosidase, and Î±-synuclein in GBA-associated Parkinsonâ€™s disease and their targeted therapeutic approaches: a comprehensive review. Translational Neurodegeneration, 2021, 10, 4.	3.6	48
155	Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote Î±-synuclein aggregation. Brain, 2022, 145, 1038-1051.	3.7	30
156	Profiling the Biochemical Signature of GBAâ€Related Parkinson's Disease in Peripheral Blood Mononuclear Cells. Movement Disorders, 2021, 36, 1267-1272.	2.2	22
157	Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Frontiers in Neurology, 2021, 12, 635958.	1.1	14
158	The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp>, Sphingolipids, Î±â€Synuclein in <scp>PD_{GBA}</scp>. Movement Disorders, 2021, 36, 1216-1228.	2.2	40
159	Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Molecular Genetics and Metabolism, 2021, 132, 49-58.	0.5	19
160	GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2215.	1.8	21
161	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiology of Aging, 2021, 103, 142.e1-142.e5.	1.5	11
162	Advancing Personalized Medicine in Common Forms of Parkinsonâ€™s Disease through Genetics: Current Therapeutics and the Future of Individualized Management. Journal of Personalized Medicine, 2021, 11, 169.	1.1	6
163	Genotype-driven therapeutic developments in Parkinsonâ€™s disease. Molecular Medicine, 2021, 27, 42.	1.9	23
164	Whole Clinic Research Enrollment in Parkinsonâ€™s Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. Journal of Parkinson's Disease, 2021, 11, 757-765.	1.5	5
165	Association of gender and age at onset with glucocerebrosidase associated Parkinsonâ€™s disease: a systematic review and meta-analysis. Neurological Sciences, 2021, 42, 2261-2271.	0.9	18
166	Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinsonâ€™s disease. Molecular Medicine, 2021, 27, 40.	1.9	24
167	Cognitive Impairment in Parkinsonâ€™s Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behavioral Sciences (Basel, Switzerland), 2021, 11, 74.	1.0	39
168	Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques. International Journal of Molecular Sciences, 2021, 22, 4825.	1.8	18
169	Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinsonâ€™s disease. Nature Genetics, 2021, 53, 787-793.	9.4	82

#	Article	IF	Citations
170	Exploring the Genotypeâ€“Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Frontiers in Neurology, 2021, 12, 694764.	1.1	28
171	Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 636139.	1.1	26
172	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	1.1	6
173	Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. Frontiers in Neurology, 2021, 12, 681369.	1.1	10
174	The Genetics of Parkinsonâ€™s Disease and Implications for Clinical Practice. Genes, 2021, 12, 1006.	1.0	81
175	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinsonâ€™s disease patients. Journal of Neurology, 2022, 269, 1485-1500.	1.8	24
176	Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinsonâ€™s Disease Cohorts. Journal of Parkinson's Disease, 2021, 11, 1569-1578.	1.5	5
177	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2021, 83, 269-279.	1.2	10
178	Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 190-195.	2.2	19
179	Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. Frontiers in Neurology, 2021, 12, 723476.	1.1	5
180	Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. Frontiers in Neurology, 2021, 12, 648588.	1.1	23
181	Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radical Biology and Medicine, 2021, 175, 42-55.	1.3	12
182	The role of amyloids in Alzheimer's and Parkinson's diseases. International Journal of Biological Macromolecules, 2021, 190, 44-55.	3.6	33
183	Parkinson's disease: Genetic-driven therapeutic approaches. , 2021, , 135-159.		0
184	<scp>CSF NFL</scp> in a Longitudinally Assessed <scp>PD</scp> Cohort: Age Effects and Cognitive Trajectories. Movement Disorders, 2020, 35, 1138-1144.	2.2	36
188	Patientsâ€™ experiences of Parkinsonâ€™s disease: a qualitative study in glucocerebrosidase and idiopathic Parkinsonâ€™s disease. Journal of Patient-Reported Outcomes, 2020, 4, 65.	0.9	10
189	The SPID-GBA study. Neurology: Genetics, 2020, 6, e523.	0.9	37
190	Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology, 2021, 96, e1036-e1044.	1.5	17

#	Article	IF	Citations
191	Cognitive Profile and Markers of Alzheimer Diseaseâ€“Type Pathology in Patients With Lewy Body Dementias. Neurology, 2021, 96, e1855-e1864.	1.5	28
192	Long-Term Outcomes of Genetic Parkinsonâ€™s Disease. Journal of Movement Disorders, 2020, 13, 81-96.	0.7	21
193	Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinsonâ€™s Disease. , 0, , 45-64.		5
194	Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with <scp>GBA</scp> Mutations. Movement Disorders, 2022, 37, 106-118.	2.2	13
195	New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology, 2022, 202, 108822.	2.0	33
196	Mapping the Diverse and Inclusive Future of Parkinsonâ€™s Disease Genetics and Its Widespread Impact. Genes, 2021, 12, 1681.	1.0	7
197	Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Scientific Reports, 2021, 11, 20945.	1.6	14
199	Genetic Factors Influencing the Development and Treatment of Cognitive Impairment and Psychosis in Parkinsonâ€™s Disease. , 2019, , 359-370.		0
201	Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease. , 2020, , 67-81.		1
204	Progression of symptoms in Parkinson's disease. , 2020, , 3-20.		1
205	Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	1
206	Parkinsonâ€™s Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae, 2021, 13, 70-78.	1.7	6
207	Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinsonâ€™s disease: mutational spectrum and clinical features. Journal of Neural Transmission, 2022, 129, 37-48.	1.4	18
208	Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease. Npj Parkinson's Disease, 2021, 7, 104.	2.5	12
209	Alpha-Synuclein and Cognitive Decline in Parkinson Disease. Life, 2021, 11, 1239.	1.1	18
210	Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinsonâ€™s disease enrolled in PPMI. Npj Parkinson's Disease, 2021, 7, 102.	2.5	19
211	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <scp>GBA</scp> Mutation Carriers. Annals of Neurology, 2022, 91, 424-435.	2.8	46
212	Intestinal Inflammation and Parkinsonâ€™s Disease. , 2021, 12, 2052.		23

#	Article	IF	Citations
213	Parkinsonâ€™s Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering. Diagnostics, 2022, 12, 112.	1.3	12
214	Prevalence and genotypeâ€“phenotype correlations of GBAâ€related Parkinson disease in a large Chinese cohort. European Journal of Neurology, 2022, 29, 1017-1024.	1.7	12
215	Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 651-652.	2.2	4
216	LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Translational Neurodegeneration, 2022, 11, 5.	3.6	21
217	<scp>GBA</scp> and <scp>APOE</scp> Impact Cognitive Decline in Parkinson's Disease: A 10â€Year Populationâ€Based Study. Movement Disorders, 2022, 37, 1016-1027.	2.2	45
218	Genetics of cognitive dysfunction in Parkinson's disease. Progress in Brain Research, 2022, 269, 195-226.	0.9	6
219	Ambroxol reverses tau and Î±-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Human Molecular Genetics, 2022, 31, 2396-2405.	1.4	10
220	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinsonâ€™s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. Journal of Parkinson's Disease, 2022, 12, 557-570.	1.5	34
221	Genetics of Non-Motor Symptoms of Parkinsonâ€™s Disease. , 2022, , 199-211.		0
222	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinsonâ€™s Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	1.7	7
223	Dysautonomia in Parkinsonâ€™s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control. Frontiers in Neuroscience, 2022, 16, 842498.	1.4	6
224	Immune Response Modifications in the Genetic Forms of Parkinsonâ€™s Disease: What Do We Know?. International Journal of Molecular Sciences, 2022, 23, 3476.	1.8	5
225	Role of Lysosomal Gene Variants in Modulating <scp>GBA</scp>â€Associated Parkinson's Disease Risk. Movement Disorders, 2022, 37, 1202-1210.	2.2	17
226	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	1.8	61
228	Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease, 2022, 166, 105663.	2.1	34
229	Cognitive Impairment in Genetic Parkinsonâ€™s Disease. Parkinson's Disease, 2021, 2021, 1-11.	0.6	3
230	DiagnÃ³sticos FonoaudiolÃ³gicos y SÃntomas no Motores en Pacientes con Enfermedad de Parkinson. AretÃ©, 2020, 20, 63-71.	0.1	0
231	Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation. Parkinsonism and Related Disorders, 2022, , .	1.1	0

#	Article	IF	Citations
232	Clinical Sphingolipids Pathway in Parkinsonâ€™s Disease: From GCase to Integrated-Biomarker Discovery. Cells, 2022, 11, 1353.	1.8	7
234	Neuroimaging in Glucocerebrosidaseâ€Associated Parkinsonism: A Systematic Review. Movement Disorders, 2022, 37, 1375-1393.	2.2	15
235	Imaging and genetics in Parkinsonâ€™s disease: assessment of the GBA1 mutation. Journal of Neurology, 2022, 269, 5347-5355.	1.8	2
236	A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies. Journal of Parkinson's Disease, 2022, 12, 1703-1725.	1.5	4
237	GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 2022, 129, 1219-1233.	1.4	22
239	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Frontiers in Neurology, 0, 13, .	1.1	6
240	Prevalence and clinical aspects of depression in Parkinsonâ€™s disease: A systematic review and metaâ€‘analysis of 129 studies. Neuroscience and Biobehavioral Reviews, 2022, 141, 104749.	2.9	29
241	Recent advances in Lewy body dementia: A comprehensive review. Disease-a-Month, 2023, 69, 101441.	0.4	3
242	Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinsonâ€™s Disease Patients from Tamil Nadu Population, India. Journal of Molecular Neuroscience, 2022, 72, 1724-1737.	1.1	9
244	Genomeâ€Wide Polygenic Score Predicts Large Number of High Risk Individuals in Monogenic Undiagnosed Young Onset Parkinson's Disease Patients from India. Advanced Biology, 2022, 6, .	1.4	5
245	Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants. Journal of the Neurological Sciences, 2022, 440, 120354.	0.3	3
246	Î²-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration. Cells, 2022, 11, 2343.	1.8	8
247	Glucocerebrosidase mutations and Parkinson disease. Journal of Neural Transmission, 2022, 129, 1105-1117.	1.4	19
248	Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Frontiers in Neurology, 0, 13, .	1.1	7
249	Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study. Parkinsonism and Related Disorders, 2022, 103, 169-174.	1.1	4
250	Steering the genes into the field of deep brain stimulation. Parkinsonism and Related Disorders, 2022, 103, 166-168.	1.1	1
251	Precision Medicine in Parkinsonâ€™s Disease: From Genetic Risk Signals to Personalized Therapy. Brain Sciences, 2022, 12, 1308.	1.1	6
252	The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. Human Molecular Genetics, 0, , .	1.4	5

#	Article	IF	Citations
253	GBA1 and The Immune System: A Potential Role in Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2022, 12, S53-S64.	1.5	3
255	ANTIOXIDANT ROLE OF DJ-1 PROTEIN IN THE PATHOGENESIS OF PARKINSON'S DISEASE. Eurasian Journal of Applied Biotechnology, 2022, , 3-13.	0.0	0
256	Dualâ€phase ¹⁸Fâ€FPâ€CIT positron emission tomography and cardiac ¹²³Iâ€MIBG scintigraphy of Parkinson's disease patients with GBA mutations: evidence of the bodyâ€first type?. European Journal of Neurology, 2023, 30, 344-352.	1.7	7
257	Diagnosis and Medical Management of Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 1281-1300.	0.4	1
258	Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease. Neurology, 2023, 100, .	1.5	10
259	Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinsonâ€™s Disease. Genes, 2022, 13, 1937.	1.0	4
260	Unraveling Parkinsonâ€™s Disease Neurodegeneration: Does Aging Hold the Clues?. Journal of Parkinson's Disease, 2022, 12, 2321-2338.	1.5	9
261	Polygenic risk scores: An overview from bench to bedside for personalised medicine. Frontiers in Genetics, 0, 13, .	1.1	17
262	Neuronopathic GBA1L444P Mutation Accelerates Glucosylsphingosine Levels and Formation of Hippocampal Alpha-Synuclein Inclusions. Journal of Neuroscience, 2023, 43, 501-521.	1.7	4
263	The Consequences of GBA Deficiency in the Autophagyâ€“Lysosome System in Parkinsonâ€™s Disease Associated with GBA. Cells, 2023, 12, 191.	1.8	9
264	Motor and non-motor features in Parkinsonâ€™s Disease patients carrying GBA gene mutations. Acta Neurologica Belgica, 2023, 123, 221-226.	0.5	2
265	Classification of <scp>GBA1</scp> Variants in Parkinson's Disease: The <scp>GBA1â€PD</scp> Browser. Movement Disorders, 2023, 38, 489-495.	2.2	18
266	Perinatal lethal Gaucher disease due to compound heterozygosity of the splicing mutations in GBA gene. Taiwanese Journal of Obstetrics and Gynecology, 2023, 62, 175-178.	0.5	0
267	GBA1 Gene Mutations in Î±-Synucleinopathiesâ€”Molecular Mechanisms Underlying Pathology and Their Clinical Significance. International Journal of Molecular Sciences, 2023, 24, 2044.	1.8	10
268	Genetic Movement Disorders Commonly Seen in Asians. Movement Disorders Clinical Practice, 2023, 10, 878-895.	0.8	5
269	A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene. Npj Parkinson's Disease, 2023, 9, .	2.5	2
270	Should we offer deep brain stimulation to Parkinsonâ€™s disease patients with GBA mutations?. Frontiers in Neurology, 0, 14, .	1.1	6
271	Acid ceramidase involved in pathogenic cascade leading to accumulation of Î±-synuclein in iPSC model of GBA1-associated Parkinsonâ€™s disease. Human Molecular Genetics, 2023, 32, 1888-1900.	1.4	2

#	Article	IF	Citations
272	Association of GBA genotype with motor and cognitive decline in Chinese Parkinsonâ€™s disease patients. Frontiers in Aging Neuroscience, 0, 15, .	1.7	3
273	Genetic mechanism vs genetic subtypes: The example of GBA. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 155-170.	1.0	3
274	Recent Advances in the Treatment of Genetic Forms of Parkinsonâ€™s Disease: Hype or Hope?. Cells, 2023, 12, 764.	1.8	3
275	Predictors of cognitive impairment in newly diagnosed Parkinsonâ€™s disease with normal cognition at baseline: A 5-year cohort study. Frontiers in Aging Neuroscience, 0, 15, .	1.7	3
276	ClinicalÂand genetic analysis of Vietnamese patients diagnosed with earlyâ€onset Parkinson's disease. Brain and Behavior, 2023, 13, .	1.0	6
277	Differences in Survival across Monogenic Forms of Parkinson's Disease. Annals of Neurology, 2023, 94, 123-132.	2.8	5
278	A Biomarker Study in Patients with GBA1â€Parkinson's Disease and Healthy Controls. Movement Disorders, 2023, 38, 783-795.	2.2	4
279	Genetic Evidence for Endolysosomal Dysfunction in Parkinsonâ€™s Disease: A Critical Overview. International Journal of Molecular Sciences, 2023, 24, 6338.	1.8	2
280	<scp>LRRK2</scp> and Parkinson's disease: from genetics to targeted therapy. Annals of Clinical and Translational Neurology, 2023, 10, 850-864.	1.7	5
281	Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. , 2023, 246, 108419.		3
286	Perspective on the current state of the LRRK2 field. Npj Parkinson's Disease, 2023, 9, .	2.5	10
287	More than meets the eye in Parkinsonâ€™s disease and other synucleinopathies: from proteinopathy to lipidopathy. Acta Neuropathologica, 2023, 146, 369-385.	3.9	8